BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Overview of attention for article published in Journal of Hematology & Oncology, March 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

twitter: 9 X users

Readers on

mendeley: 52 Mendeley

Summary X

So far, Altmetric has seen 12 X posts from 9 X users, with an upper bound of 18,659 followers.

#kras #g12c #krasg12c

11 Mar 2022

Reply Repost Favourite

RT @Trankill34: BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers https://t.co/kOPE…

10 Mar 2022

Reply Repost Favourite

RT @KRHornberger: New study showing synergy between the Bcl-xL degrader DT2216 and the KRAS-G12C inhibitor sotorasib, both in vitro and in…

10 Mar 2022

Reply Repost Favourite

New study showing synergy between the Bcl-xL degrader DT2216 and the KRAS-G12C inhibitor sotorasib, both in vitro and in vivo. https://t.co/Pm8aobdOY2

10 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.